NCT05170893 is a NA clinical trial of Coenzyme Q10 in Hemodialysis, sponsored by Ain Shams University.

Who is sponsoring NCT05170893?

NCT05170893 is sponsored by Ain Shams University.

What drugs are being tested in NCT05170893?

Interventions in NCT05170893: Coenzyme Q10, Placebo.

What condition does NCT05170893 study?

NCT05170893 studies Hemodialysis.

Is NCT05170893 still recruiting?

NCT05170893 is currently completed. Last updated 19 July 2023.

Last reviewed 2023-07-19 · How we verify

NCT05170893

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Coenzyme Q10 in Pediatric Hemodialysis Patients

Completed NA Last updated 19 July 2023

What this trial tests

NA trial testing Coenzyme Q10 in Hemodialysis in 36 participants. Completed in 26 July 2022.

Timeline

17 January 2022

Primary endpoint
14 July 2022

26 July 2022

Quick facts

Lead sponsor	Ain Shams University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	36
Start date	17 January 2022
Primary completion	14 July 2022
Estimated completion	26 July 2022
Sites	1 location across Egypt

Drugs / interventions tested

Coenzyme Q10 — full drug profile →
Placebo

Conditions studied

Hemodialysis — all drugs for Hemodialysis →

Sponsor

Ain Shams University

Who can join

Adults 2 to 18, any sex, with Hemodialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

All chronic kidney disease patients, whether on regular hemodialysis or not, are at high risk of cardiovascular diseases. This is mainly due to increased oxidative stress, reduced antioxidants and generalized inflammation. Coenzyme Q10 is a vitamin-like antioxidant synthesized in almost all body cells, and it is also available in many dietary sources. It was observed that chronic kidney disease patients have low plasma levels of Coenzyme Q10. Clinical benefits of Coenzyme Q10 supplementation have been documented for various cardiovascular and neurodegenerative disorders. The investigators believe that Coenzyme Q10 supplementation may have potential benefits in pediatric patients receiving hemodialysis; mainly due to its antioxidant activity and anti-inflammatory effects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Coenzyme Q10

Trials testing the same drug.

NCT06743802 — The Effect of Coenzyme Q10 in Preventing Pain After Thoracoscopic Surgery · Phase 4 · recruiting
NCT06856447 — The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Can · Phase 1 · recruiting
NCT07096557 — The Effect of Co-enzyme Q10 on the Clinical Outcome of Pediatric Patients With Systemic Lupus Erythematosus · Phase 2 · completed
NCT06040905 — Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) · NA · recruiting
NCT05873673 — Coenzyme Q10 and Dentoalveolar Cyst · Phase 2 · active not recruiting

Other recruiting trials for Hemodialysis

Currently open trials in the same condition.

NCT07278973 — Hemodiafiltration Versus Hemodialysis in Older People · NA · recruiting
NCT07438925 — Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure Variation · active not recruiting
NCT07234890 — Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury. · Phase 2 · recruiting
NCT07512895 — The Effect of Progressive Muscle Relaxation Exercises on Depression and Fatigue in Patients Receiving Hemodialysis Treat · NA · recruiting
NCT07076888 — Aerobic Exercises and Hemodialysis Patients · NA · recruiting

Other Ain Shams University trials

Trials by the same sponsor.

NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05170893 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
Last refreshed: 19 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05170893.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing